Anji Pharmaceuticals Inc., of Cambridge, Mass., said it acquired global development rights for a delayed-release formulation of metformin originally developed by Elcelyx Therapeutics Inc., of San Diego, designed to target delivery to the lower small intestine. Terms of the deal were not disclosed. Anji plans to start a pivotal phase III study in chronic kidney disease later this year.